Skip to content
Angion Biomedica Corp

Angion Biomedica Corp

ANGION IS A LATE-STAGE CLINICAL COMPANY DEVELOPING SMALL MOLECULES TARGETING ACUTE ORGAN INJURY AND CHRONIC FIBROSIS

  • about
    • executive management
    • scientific advisory board
    • board of directors
  • our science
    • HGF/c-Met Pathway
    • Acute Kidney Injury
    • Acute Lung Injury
    • CNS Injury
  • pipeline
    • ANG-3777
    • ANG-3070
    • ROCK2 Inhibitor
    • CYP11B2 Inhibitor
  • investors
  • publications
  • careers
  • contact

investors

PRESS RELEASES

November 9, 2020
Vifor Pharma and Angion Sign License Agreement for ANG-3777 in Nephrology Indications
October 9, 2020
Angion to Present Multiple Posters at Kidney Week 2020
August 4, 2020
Angion Enrolls First Patients in Phase 2 Clinical Trial of ANG-3777 in Patients with Acute Lung Injury Associated with COVID-19 Pneumonia
July 8, 2020
Angion Initiates Phase 2 Clinical Trial of ANG-3777 in Patients with Acute Lung Injury Associated with COVID-19 Pneumonia
see more

EVENTS

Stay tuned for future events

CORPORATE PRESENTATION

CORPORATE ADDRESS

51 Charles Lindbergh Boulevard
Uniondale, NY 11553

Navigation

  • home
  • about
  • our science
  • pipeline
  • investors
  • publications
  • careers
  • contact

© 2021 Angion. All Rights Reserved.
Legal and Privacy Policy

NEW YORK | SAN FRANCISCO | BOSTON